Insulin aspart Sanofi® receives EU marketing authorization, broadening options and increasing treatment choice for people with diabetes
- Category: Proteins and Peptides
- Published on Monday, 06 July 2020 13:56
- Hits: 1657
PARIS, France I July 03, 2020 I Insulin aspart Sanofi® (insulin aspart 100 Units/mL) has received EU marketing authorization, and will provide another treatment option for adults, adolescents and children aged 1 year and above who have diabetes. The decision follows recent positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). Insulin aspart Sanofi® rounds out Sanofi’s comprehensive insulin portfolio which already includes two rapid-acting insulin analogs approved by European regulators.